^
    Back
    Association details:
    Biomarker:FGFR2 mutation
    Cancer:Cholangiocarcinoma
    Drug:KIN-3248 (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Kinnate Bio Press Release
    Title:

    Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

    Published date:
    02/14/2023
    Excerpt:
    Kinnate Biopharma...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate’s investigational pan-FGFR inhibitor, KIN-3248, for the treatment of patients with unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other alterations, who have received at least one prior systemic therapy.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO-GI 2022
    Title:

    Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations

    Published date:
    01/18/2022
    Excerpt:
    ...KIN-3248 led to dose-dependent tumor growth inhibition and regressions in FGFR inhibitor-resistant, patient-derived gastric cancer and cholangiocarcinoma models harboring secondary FGFR2 kinase domain mutations.
    DOI:
    10.1200/JCO.2022.40.4_suppl.461